Search

Displaying results 8951 - 8960 of 10000 in total
  1. Drug

    Empegfilgrastim

    go.drugbank.com/drugs/DB16155
    Investigational

    Empegfilgrastim is under investigation in clinical trial NCT01569087 (Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast Cancer).

  2. Drug

    Ifidancitinib

    go.drugbank.com/drugs/DB16191
    Investigational

    Ifidancitinib is under investigation in clinical trial NCT03585296 (A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis).

  3. Drug

    Peoniflorin

    go.drugbank.com/drugs/DB16288
    Investigational

    Peoniflorin is under investigation in clinical trial NCT02878863 (Paeoniflorin Combination of Hepatoprotective Drugs Versus Hepatoprotective Drugs Only for Auto-immune Hepatitis).

  4. Drug

    Camidanlumab tesirine

    go.drugbank.com/drugs/DB16411
    Investigational

    Camidanlumab tesirine is under investigation in clinical trial NCT04639024 (ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN).

  5. Drug

    OPB-111077

    go.drugbank.com/drugs/DB16630
    Investigational

    OPB-111077 is a novel inhibitor of STAT3 and mitochondrial oxidative phosphorylation. It has demonstrated promising anticancer activity in preclinical models.

  6. Drug

    JZP-386 free base

    go.drugbank.com/drugs/DB17068
    Experimental

    JZP-386 is a deuterium-containing analog of sodium oxybate. Its safety, pharmacokinetics and pharmacodynamics were evaluated in clinical trial NCT02215499.

  7. Drug

    KAHR-102

    go.drugbank.com/drugs/DB17427
    Investigational

    KAHR-102 is a dual signaling protein fusing cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) to the Fas-ligand (FasL).

  8. Drug

    Emprumapimod

    go.drugbank.com/drugs/DB17603
    Investigational

    Emprumapimod is a potent, orally active and selective inhibitor of p38α mitogen-activated kinase inhibitor. It was investigated for dilated cardiomyopathy.

  9. Drug

    HMI-103

    go.drugbank.com/drugs/DB17684
    Investigational

    HMI-102 is an investigational gene therapy designed to encode the phenylalanine-4-hydroxylase (PAH) gene, mutated in people with phenylketonuria.

  10. Drug

    HRS-1167

    go.drugbank.com/drugs/DB18703
    Investigational

    HRS-1167 is under investigation in clinical trial NCT05473624 (Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors).